Literature DB >> 10793331

Cleavage of Bax-alpha and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line.

M Itoh1, H Chiba, T Noutomi, E Takada, J Mizuguchi.   

Abstract

Although carboplatin (CBDCA) has been used for the treatment of several types of tumors, the complete response rate has been limited, probably because of inherent or CBDCA-induced resistance. As a first step to overcome these problems, we tried to elucidate the mechanisms of CBDCA-mediated cytotoxicity in the squamous cell carcinoma cell line MIT7. The treatment of cells with CBDCA resulted in apoptosis in a dose-dependent manner, as assessed by the propidium iodide staining method and DNA degradation in a nucleosomal pattern. The induction of apoptosis was accompanied by the decline of mitochondrial membrane potential (Deltapsi(m) ) at 12 h following CBDCA stimulation. Variant forms of p18 Bax-alpha and p16 Bcl-x(L) were generated with the down-regulation of both Bax-alpha (p21) and Bcl-x(L) (p31) at 36 and 48 h following CBDCA stimulation, suggesting that the modulation of Bcl-2 family proteins Bax-alpha and Bcl-x(L) play some role in CBDCA-mediated apoptosis. The activation of caspase-3 and -8 occurred at 12 and 24 h following the stimulation, respectively. The pretreatment of cells with pan-caspase inhibitor Z-VAD-fmk markedly prevented CBDCA-mediated cytotoxicity/apoptosis and the modulation of Bcl-2 family proteins (generation of p18 Bax-alpha and p16 Bcl-x(L) ) with only slight prevention of decline of Deltapsi(m). Taken together, these results may suggest that activation of several caspases, including caspase-3 and -8, plays some role in CBDCA-mediated apoptosis, probably through the modification of Bcl-2 family proteins, Bax-alpha and Bcl-x(L). Moreover, caspase activation may occur downstream of membrane depolarization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793331     DOI: 10.1016/s1368-8375(00)00010-5

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

1.  Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans.

Authors:  R Stephanie Huang; Shiwei Duan; Emily O Kistner; Christine M Hartford; M Eileen Dolan
Journal:  Mol Cancer Ther       Date:  2008-09-02       Impact factor: 6.261

2.  Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures.

Authors:  Minnie Malik; Joy Britten; James Segars; William H Catherino
Journal:  Reprod Sci       Date:  2014-08-01       Impact factor: 3.060

3.  Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death.

Authors:  Dennis C Ko; Eric R Gamazon; Kajal P Shukla; Richard A Pfuetzner; Dale Whittington; Tarah D Holden; Mitchell J Brittnacher; Christine Fong; Matthew Radey; Cassandra Ogohara; Amy L Stark; Joshua M Akey; M Eileen Dolan; Mark M Wurfel; Samuel I Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-25       Impact factor: 11.205

4.  Honokiol-induced apoptosis and autophagy in glioblastoma multiforme cells.

Authors:  Ken-Hu Chang; Ming-DE Yan; Chih-Jung Yao; Pei-Chun Lin; Gi-Ming Lai
Journal:  Oncol Lett       Date:  2013-08-28       Impact factor: 2.967

5.  Effect of dicycloplatin, a novel platinum chemotherapeutical drug, on inhibiting cell growth and inducing cell apoptosis.

Authors:  Guang-quan Li; Xing-gui Chen; Xing-ping Wu; Jing-dun Xie; Yong-ju Liang; Xiao-qin Zhao; Wei-qiang Chen; Li-wu Fu
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

6.  IL-6 Inhibition Reduces STAT3 Activation and Enhances the Antitumor Effect of Carboplatin.

Authors:  Zhi-Yong Wang; Jun-Ai Zhang; Xian-Jin Wu; Yan-Fang Liang; Yuan-Bin Lu; Yu-Chi Gao; You-Chao Dai; Shi-Yan Yu; Yan Jia; Xiao-Xia Fu; Xiaoquan Rao; Jun-Fa Xu; Jixin Zhong
Journal:  Mediators Inflamm       Date:  2016-03-02       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.